Drug intelligence / Profile preview

AS012

Development stage: Phase 2
Lead developer: Ache Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

AS012 is an oral small molecule drug developed by Ache Laboratorios Farmaceuticos S.A. It is currently in Phase II clinical trials for the treatment of non-segmental vitiligo, a condition characterized by patchy loss of skin color. Early research suggests that AS012 may help restore skin color and could potentially reduce inflammation or modulate the immune response, offering a systemic treatment alternative to topical applications.

Beyond the preview

Go deeper on AS012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS012.

Explore the full profile